Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Metastatic Pancreas Cancer Treatment Approaches

July 24th 2019

Practical Advice: Pancreas Cancer Adjuvant Therapy

July 24th 2019

Pancreatic Cancer Adjuvant Therapy

July 24th 2019

Borderline Resectable Pancreatic Cancer

July 24th 2019

Changing Role of Surgery in Pancreatic Cancer

July 24th 2019

Genomic Testing in Pancreatic Cancer

July 24th 2019

Practical Considerations for Pancreatic Cancer Genetic Testing

July 24th 2019

Advanced Pancreatic Cancer and Molecular Testing

July 24th 2019

Finn Sheds Light on Single-Agent Pembrolizumab Data in Advanced HCC

July 23rd 2019

Richard S. Finn, MD, discusses results from the KEYNOTE-240 trial and explained how they are still clinically meaningful for patients with hepatocellular carcinoma.

FDA Grants Breakthrough Designation to Frontline Pembrolizumab/Lenvatinib for HCC

July 23rd 2019

The FDA has granted a breakthrough therapy designation to the combination of pembrolizumab and lenvatinib for the first-line treatment of patients with advanced unresectable hepatocellular carcinoma that is not amenable to locoregional therapy.

Dr. Cohn on Frontline Therapies in Metastatic Pancreatic Cancer

July 23rd 2019

Allen L. Cohn, MD, medical oncologist, Rocky Mountain Cancer Centers, discusses frontline therapies in metastatic pancreatic cancer.

Dr. Fukuoka on Dosage for Regorafenib/Nivolumab Combo in Gastric Cancer and CRC

July 22nd 2019

Shota Fukuoka, MD, physician, National Cancer Center in Japan, discusses finding the recommended dosage of regorafenib plus nivolumab in patients with advanced gastric cancer or colorectal cancer.

Dr. Messersmith on the Rise of Molecular Testing in mCRC

July 19th 2019

Wells A. Messersmith, MD, co-leader of the Developmental Therapeutics Program, and director, GI Cancer Program, at the University of Colorado School of Medicine, discusses the rise of molecular testing in metastatic colorectal cancer (mCRC).

Dr. El-Khoueiry on Choosing Between Immunotherapy Agents and TKIs in HCC

July 19th 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses choosing between immunotherapy agents and TKIs in hepatocellular carcinoma (HCC).

Regorafenib/Nivolumab Combo to Be Explored in Phase III MSS CRC Trial

July 18th 2019

The combination of regorafenib and nivolumab will be compared with regorafenib alone in a phase III trial of patients with microsatellite stable colorectal cancer, following encouraging phase Ib findings of the REGONIVO study.

Drug Development and Final Thoughts

July 18th 2019

Novel and Combination Therapies for the Treatment of Gastric Cancer

July 18th 2019

Interpretation of Data on Immunotherapy Use in Gastric Cancer

July 18th 2019

The Role of Immunotherapy in Gastric Cancer

July 18th 2019

Ramucirumab for Progressive Disease in Gastric Cancer

July 18th 2019